In vivo antitumor activity and in vitro cytotoxic properties of bis[1,2-bis(diphenylphosphino)ethane]gold(I) chloride.

We have previously reported the cytotoxicity and antitumor activity of bis(diphenylphosphino)ethane (DPPE) and a variety of its transition metal complexes. During studies of the chemistry of a gold complex of this group [(AuCl)2(DPPE)], it was observed that this complex readily underwent ring closure on reaction with DPPE to form the tetrahedral complex [Au(DPPE)2]+. Various counterion forms (e.g., Cl-) of this cation were isolated and were found to exhibit a remarkably high stability in solution. Evaluation of [Au(DPPE)2]Cl in mice bearing i.p. P388 leukemia demonstrated that the compound produced an average of 87% increase in life span at its maximally tolerated dose (2-3 mumol/kg/day for 5 days). Activity was also seen in i.p. M5076 reticulum cell sarcoma (60% increase in life span) and s.c. mammary adenocarcinoma 16/c. Modest activity was evident in i.p. B16 melanoma and L1210 leukemia. A subline of P388 leukemia resistant to cisplatin was not cross-resistant to [Au(DPPE)2]Cl. In addition, combination therapy of [Au(DPPE)2]Cl and cisplatin against i.p. P388 demonstrated an advantage over single-agent therapy. In vitro studies of [Au(DPPE)2]Cl showed that the compound: is cytotoxic to tumor cell lines; is only minimally inhibited in its cytotoxic activity by the presence of serum; produces DNA protein cross-links and DNA strand breaks in cells; and inhibits macromolecular synthesis with a preferential inhibitory effect on protein synthesis relative to DNA and RNA synthesis. 31P nuclear magnetic resonance spectroscopy indicated that the compound is stable in the presence of serum proteins, thiols, or disulfides and that it reacts with Cu(II) resulting in the formation of a Cu(I)DPPE complex. The results of these in vivo and in vitro experiments suggest that the contrasting pharmacological profile of [Au(DPPE)2]Cl with respect to other gold(I) phosphine complexes may be related to both the kinetic stability of the complex and its stability in the presence of thiols.

[1]  J. Cadogan,et al.  Tervalent phosphorus compounds in organic synthesis , 1974 .

[2]  P. Sadler,et al.  The Design of Metal Complexes as Anticancer Drugs , 1984 .

[3]  N. Tanaka,et al.  DNA strand scission induced by adriamycin and aclacinomycin A. , 1979, The Journal of antibiotics.

[4]  P. Jones X-ray structural investigations of gold compounds , 1981 .

[5]  B. Hill,et al.  In vitro responses of human prostate tumour cell lines to a range of antitumour agents , 1983, International journal of cancer.

[6]  W. E. Hill,et al.  31 P n.m.r. study of tertiary phosphine complexes of gold(I) , 1979 .

[7]  Peter J. Sadler,et al.  Bis((diphenylphosphino)(diethylphosphino)ethane)copper(1+) chloride: a chelated copper(I) complex with tetrahedral stereochemistry. Rate of inversion compared with those of isostructural silver(I) and gold(I) complexes , 1986 .

[8]  P. Sadler,et al.  Ligand Exchange Reactions of Gold Drugs in Model Systems and in Red Cells , 1983 .

[9]  S. Crooke,et al.  Deoxyribonucleic acid breaks produced by 4'-(9-acridinylamino)methanesulfon-m-anisidide and copper. , 1984, Biochemistry.

[10]  O. Burrone,et al.  Effect of auranofin on DNA and protein synthesis in human lymphocytes. , 1977, The Journal of rheumatology.

[11]  S. Crooke,et al.  Effects of coordinated gold compounds on in vitro and in situ DNA replication. , 1985, Biochemical pharmacology.

[12]  S. Crooke,et al.  Interactions of gold coordination complexes with DNA. , 1986, Biochemical pharmacology.

[13]  P. Jones Is regular tetrahedral geometry possible in gold(I)–phosphine complexes? X-Ray crystal structures of three modifications of (PPh3)4Au+BPh4– , 1980 .

[14]  M. J. Mays,et al.  Structure and bonding in gold(I) compounds. Part 4. A phosphorus-31 nuclear magnetic study of the structure of some gold(I) phosphine complexes in solution , 1979 .

[15]  S. Crooke,et al.  Correlation of the in vitro cytotoxic and in vivo antitumor activities of gold(I) coordination complexes. , 1986, Journal of medicinal chemistry.

[16]  S. Crooke,et al.  Evaluation of the in vivo antitumor activity and in vitro cytotoxic properties of auranofin, a coordinated gold compound, in murine tumor models. , 1985, Cancer research.

[17]  S. Crooke,et al.  Cellular association, intracellular distribution, and efflux of auranofin via sequential ligand exchange reactions. , 1986, Biochemical pharmacology.

[18]  B. Barlogie,et al.  Patterns of cell survival following treatment with antitumor agents in vitro. , 1979, European journal of cancer.